A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy

A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy

The chemotherapeutics sorafenib and regorafenib inhibit shedding of MHC class I-related chain A (MICA) from hepatocellular carcinoma (HCC) cells by suppressing a disintegrin and metalloprotease 9 (ADAM9). MICA is a ligand for natural killer (NK) group 2 member D (NKG2D) and is expressed on tumor cel...

Full description

Bibliographic Details
Main Authors: Sooyeon Oh, YoungJoon Park, Hyun-Jung Lee, Jooho Lee, Soo-Hyeon Lee, Young-Seok Baek, Su-Kyung Chun, Seung-Min Lee, Mina Kim, Young-Eun Chon, Yeonjung Ha, Yuri Cho, Gi Jin Kim, Seong-Gyu Hwang, KyuBum Kwack
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
hepatocellular carcinoma
a disintegrin and metalloprotease 9
nivolumab
natural killer
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/12/3/745

Internet

https://www.mdpi.com/2072-6694/12/3/745

Similar Items